Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EBT (2021 - 2026)

bioAffinity Technologies has reported EBT over the past 5 years, most recently at -$3.6 million for Q1 2026.

  • Quarterly EBT fell 36.92% to -$3.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$15.8 million through Mar 2026, down 62.98% year-over-year, with the annual reading at -$14.9 million for FY2025, 64.66% down from the prior year.
  • EBT was -$3.6 million for Q1 2026 at bioAffinity Technologies, down from -$3.1 million in the prior quarter.
  • Over five years, EBT peaked at -$88052.0 in Q2 2022 and troughed at -$5.0 million in Q3 2025.
  • The 5-year median for EBT is -$2.3 million (2023), against an average of -$2.6 million.
  • The largest YoY upside for EBT was 53.48% in 2023 against a maximum downside of 1871.09% in 2023.
  • A 5-year view of EBT shows it stood at -$1.7 million in 2022, then plummeted by 41.58% to -$2.4 million in 2023, then fell by 25.14% to -$3.0 million in 2024, then dropped by 5.64% to -$3.1 million in 2025, then fell by 15.84% to -$3.6 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's EBT are -$3.6 million (Q1 2026), -$3.1 million (Q4 2025), and -$5.0 million (Q3 2025).